Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
  • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4

Definitions

• This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha- la adrenoceptor antagonists. More particularly, the compounds of the present invention are useful for treating benign prostatic hype ⁇ lasia (BPH).
• BPH benign prostatic hype ⁇ lasia
• Human adrenergic receptors are integral membrane proteins which have been classified into two broad classes, the alpha and the beta adrenergic receptors. Both types mediate the action of the peripheral sympathetic nervous system upon binding of catecholamines, norepinephrine and epinephrine. Norepinephrine is produced by adrenergic nerve endings, while epinephrine is produced by the adrenal medulla.
• the binding affinity of adrenergic receptors for these compounds forms one basis of the classification: alpha receptors bind norepinephrine more strongly than epinephrine and much more strongly than the synthetic compound isoproterenol. The binding affinity of these hormones is reversed for the beta receptors. In many tissues, the functional responses, such as smooth muscle contraction, induced by alpha receptor activation are opposed to responses induced by beta receptor binding.
• alpha and beta receptors were further subdivided into a ⁇ _ ot2, Bl , and ⁇ 2 subtypes. Functional differences between ⁇ i and oc2 receptors have been recognized, and compounds which exhibit selective binding between these two subtypes have been developed.
• WO 92/0073 the selective ability of the R(+) enantiomer of terazosin to selectively bind to adrenergic receptors of the alpha 1 subtype was reported.
• the ⁇ i/oc2 selectivity of this compound was disclosed as being significant because agonist stimulation of the oc2 receptors was said to inhibit secretion of epinephrine and norepinephrine, while antagonism of the ⁇ 2 receptor was said to increase secretion of these hormones.
• non- selective alpha-adrenergic blockers such as phenoxybenzamine and phentolamine, is limited by their oc2 adrenergic receptor mediated induction of increased plasma catecholamine concentration and the attendant physiological sequelae (increased heart rate and smooth muscle contraction).
• Adrenoreceptors Molecular Biology. Biochemistry and Pharmacology. (Progress in Basic and Clinical Pharmacology series, Karger, 1991 ), wherein the basis of i/ ⁇ 2 subclassification, the molecular biology, signal transduction (G-protein interaction and location of the significant site for this and ligand binding activity away from the 3'-terminus of alpha adrenergic receptors), agonist structure-activity relationships, receptor functions, and therapeutic applications for compounds exhibiting ⁇ -adrenergic receptor affinity was explored.
• Benign prostatic hype ⁇ lasia also known as benign prostatic hypertrophy or BPH
• BPH benign prostatic hypertrophy
• the symptoms of the condition include, but are not limited to, increased difficulty in urination and sexual dysfunction. These symptoms are induced by enlargement, or hype ⁇ lasia, of the prostate gland. As the prostate increases in size, it impinges on free ⁇ flow of fluids through the male urethra. Concommitantly, the increased noradrenergic innervation of the enlarged prostate leads to an increased adrenergic tone of the bladder neck and urethra, further restricting the flow of urine through the urethra.
• alfuzosin which is reported in EP 0 204597 to induce urination in cases of prostatic hype ⁇ lasia.
• terazosin the selective ability of the R(+) enantiomer of terazosin to bind to adrenergic receptors of the i subtype was reported.
• terazosin, doxazosin, prazosin, bunazosin, indoramin, alfuzosin were disclosed. However, no information as to the ⁇ ia.
• rat tissues have been used to screen for potential adrenergic receptor antagonists.
• compounds which appear active in animal tissue may not be active or sufficiently selective in humans. This results in substantial wastage of time and effort, particularly where high volume compound screening programs are employed.
• compounds, which might be highly effective in humans would be missed because of their absence of appreciable affinity for the heterologous animal receptors.
• even single amino acid changes between the sequence of biologically active proteins in one species may give rise to substantial pharmacological differences.
• WO94/08040 published 14 April 1994 and WO94/10989, published 26 May 1994
• a cloned human ⁇ i c adrenergic receptor and a method for identifying compounds which bind the human ⁇ i c receptor has now made possible the identification of selective human ⁇ ic adrenergic receptor antagonists useful for treating BPH.
• the instant patent disclosure discloses novel compounds which selectively bind to the human ⁇ i c receptor. These compounds are further tested for binding to other human alpha 1 receptor subtypes, as well as counterscreened against other types of receptors, thus defining the specificity of the compounds of the present invention for the human ⁇ i c adrenergic receptor.
• compounds of this invention are used to reduce the acute symptoms of BPH.
• compounds of this invention may be used alone or in conjunction with a more long-term anti-BPH therapeutics, such as testosterone 5-alpha reductase inhibitors, including PROSCAR® (finasteride).
• a more long-term anti-BPH therapeutics such as testosterone 5-alpha reductase inhibitors, including PROSCAR® (finasteride).
• these compounds may be used to induce highly tissue-specific, localized ⁇ i c adrenergic receptor blockade whenever this is desired. Effects of this blockade include reduction of intra-ocular pressure, control of cardiac arrhythmias, and possibly a host of alpha- lc receptor mediated central nervous system events.
• ⁇ i adrenergic receptor ( ⁇ ] -AR) classification scheme similar to that proposed by Ford, et al. [ ⁇ _ z Adrenoceptor Classification: Sha ⁇ ening Occam's Razor. Trends in Pharm. Sci. 1994, L5, 167-170] was adopted at the August, 1994 meeting of the International Union of Pharmacology (IUPHAR) in Montreal, Canada.
• the ⁇ i -AR genes formerly known as ⁇ ia/d, «lb and ⁇ ic were renamed aid, alb and ⁇ ia, respectively.
• This new naming system reflects the correspondence between the proteins encoded by the ⁇ ia and ⁇ ib genes (new IUPHAR nomenclature) and the receptors characterized by traditional pharmacological means as ⁇ iA and ⁇ iB, respectively, in the literature. Recombinant receptors and receptors characterized pharmacologically in tissues are distinguished by lowercase and uppercase subscripts, respectively.
• the present invention provides compounds for the treatment of urinary obstruction caused by benign prostatic hype ⁇ lasia (BPH).
• BPH benign prostatic hype ⁇ lasia
• the compounds selectively antagonize the human alpha-la adrenergic receptor at nanomolar and subnanomolar concentrations while exhibiting at least ten fold lower affinity for the alpha- Id and alpha- lb human adrenergic receptors and many other G-protein coupled receptors.
• This invention has the advantage over non-selective alpha- 1 adrenoceptor antagonists of reduced side effects related to peripheral adrenergic blockade. Such side effects include orthostatic hypotension, syncope, lethargy, etc.
• the compounds of the present invention have the structure:
• V is selected from carbon or nitrogen, provided that when V is nitrogen, then R ⁇ is absent;
• Y is selected from oxygen, NR ⁇ or sulfur;
• Z is selected from CH, CCO2R 5 , CH(CH2)qC ⁇ 2(R 5 )2, COR 12, CNR 12R 13 or C(CH2)qCN(R )2; or Z-R14 forms a cyclopropyl ring;
• R 1 is selected from unsubstituted, mono- or poly-substituted phenyl where the substitutents on the phenyl are independently selected from halogen, cyano, CO2R 5 , OR 5 , (CH2)qCON(R 5 )2, (CH2)qC ⁇ 2R 5 , methylenedioxy when the phenyl ring is di-substituted and the substituents are on adjacent carbon atoms, C ⁇ _4 alkyl or halogen substituted Ci -4 alkyl; or unsubstituted, mono- or poly-substituted: pyridyl, thienyl, furanyl or naphthyl where the substituents on the pyridyl, thienyl, furanyl or naphthyl are independently selected from CF3, phenyl, OR 5 , halogen, Ci -4 alkyl or C3-8 cycloalkyl;
• R2 is selected from hydrogen, cyano, CO2R 5 , CON(R 5 )2, tetrazole or isooxadiazole;
• R3 is selected from hydrogen, cyano, CO2R 5 , CON(R 5 )2, C1-8 alkyl, C3-8 cycloalkyl or (CH2)qC ⁇ 2R 5 ;
• R4 is selected from hydrogen, OR 5 , Cl-8 alkyl, halogen substituted
• R 5 and R6 are each independently selected from hydrogen, Cl -8 alkyl, C3-8 cycloalkyl, halogen substituted Ci-4 alkyl and halogen substituted C3-8 cycloalkyl;
• R8 is selected from hydrogen, cyano or SO2R 5 ;
• R 12 nd R 13 are each independently selected from hydrogen
• R l4 is selected from hydrogen, Cj -8 alkyl, C3-8 cycloalkyl, C1 -4 alkoxy, N(R 5 )2, mo ⁇ holinyl, piperazinyl, d-valerolactamyl, 2-pyrrolidonyl, thienyl, furanyl, pyridinyl, naphthyl or unsubstituted, mono- or poly-substituted phenyl where the substituents on the phenyl are independently selected from Cl -4 alkyl, N(R 5 )2, OR 5 or halogen;
• R 1 5 is selected from hydrogen or hydroxy
• Rl is selected from unsubstituted, mono- or poly-substituted phenyl where the substitutents on the phenyl are independently selected from halogen, cyano, CO2R 5 , OR 5 , CON(R 5 )2, methylenedioxy, Cl -4 alkyl or halogen substituted Cl -4 alkyl; pyridyl; thienyl; furanyl; or unsubstituted, mono- or poly-substituted naphthyl where the substituents on the naphthyl are independently selected from
• Z is selected from CH, CCO2R 5 , CH(CH2)qC ⁇ 2(R 5 )2, COR 12, CNR 12R 13 or C(CH2)qCN(R 5 )2;
• Rl is selected from unsubstituted, mono- or poly-substituted phenyl where the substitutents on the phenyl are independently selected from halogen, cyano, CO2R 5 , OR 5 , (CH2)qCON(R 5 )2, (CH2)qC02R 5 or Cl-4 alkyl; or unsubstituted, mono- or poly-substituted: pyridyl, thienyl, furanyl or naphthyl where the substituents on the pyridyl, thienyl, furanyl or naphthyl are independently selected from CF3, phenyl, OR 5 , halogen, C1.4 alkyl or C3-8 cycloalkyl; R4 is selected from hydrogen, OR 5 , Cl -8 alkyl or halogen;
• R l4 is selected from hydrogen, Cl -8 alkyl, C3-8 cycloalkyl, Cl-4 alkoxy, mo ⁇ holinyl, piperazinyl, ⁇ -valerolactamyl, 2-pyrrolidonyl, thienyl, furanyl, pyridinyl, naphthyl or unsubstituted, mono- or poly-substituted phenyl where the substituents on the phenyl are independently selected from Cl -4 alkyl, OR 5 or halogen; and
• R15 is hydrogen; and all other variables are as defined above;
• Rl is selected from unsubstituted, mono- or poly-substituted phenyl where the substitutents on the phenyl are independently selected from halogen, cyano, CO2R 5 , OR 5 , CON(R 5 )2 or Cl-4 alkyl; pyridyl; thienyl; furanyl; or unsubstituted, mono- or poly-substituted naphthyl where the substituent on the naphthyl are independently selected from CF3, phenyl, OR 5 , halogen, Cl-4 alkyl or C3-8 cycloalkyl; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
• Rl is selected from unsubstituted, mono- or poly-substituted phenyl where the substitutents on the phenyl are independently selected from halogen, cyano, CO2R 5 , OR 5 , CON(R 5 )2 or Cl-4 alkyl
• R2 is selected from cyano or CO2R 5 ;
• R4 is selected from hydrogen, halogen or Cl -4 alkyl
• R7 is selected from hydrogen, CF3, cyano, halogen or Cl-4 alkyl
• R l4 is selected from hydrogen, Cl-8 alkyl, C3-8 cycloalkyl or unsubstituted, mono- or poly-substituted phenyl where the substitutent on the phenyl are independently selected from halogen or Cl -4 alkyl; and where all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
• Illustrative of the invention are the compounds of the formula
• R 5 is Cl -4 alkyl
• R l4 is selected from C3-8 cycloalkyl or unsubstituted or mono ⁇ substituted phenyl wherein the substituent is selected from halogen or Cl -4 alkyl; and where all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
• R2 is selected from cyano or CO2CH3;
• R4 is selected from hydrogen, chloro or methyl
• R? is selected from hydrogen, chloro or methyl
• R l4 is selected from cyclopentyl, cyclohexyl, phenyl, p-tolyl or p-chlorophenyl; and the pharmaceutically acceptable salts thereof.
• An illustration of the invention is a pharmaceutical composition comprising a therapeutically effective amount of any of the compounds described above and a pharmaceutically acceptable carrier.
• An example of the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier.
• Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
• the composition further comprising a therapeutically effective amount of a testosterone 5-alpha reductase inhibitor.
• the testosterone 5-alpha reductase inhibitor is a type 1 , a type 2, both a type 1 and a type 2 (i.e., a three component combination comprising any of the compounds described above combined with both a type 1 testosterone 5-alpha reductase inhibitor and a type 2 testosterone 5-alpha reductase inhibitor) or a dual type 1 and type 2 testosterone 5-alpha reductase inhibitor.
• the testosterone 5-alpha reductase inhibitor is a type 2 testosterone 5-alpha reductase inhibitor.
• the testosterone 5-alpha reductase inhibitor is finasteride. More specifically illustrating the invention is a method of treating benign prostatic hype ⁇ lasia in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of any of the compounds (or any of the compositions) described above.
• the method of treating BPH wherein the compound (or composition) additionally does not cause a fall in blood pressure at dosages effective to alleviate BPH.
• Another illustration of the invention is the method of treating benign prostatic hype ⁇ lasia wherein the compound is administered in combination with a testosterone 5-alpha reductase inhibitor.
• the testosterone 5-alpha reductase inhibitor is finasteride.
• FIG. 1 Further illustrating the invention is a method of inhibiting contraction of prostate tissue or relaxing urethral smooth muscle in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of any of the compounds (or any of the compositions) described above.
• More specifically exemplifying the invention is the method of inhibiting contraction of prostate tissue or relaxing urethral smooth muscle wherein the compound (or composition) additionally does not cause a fall in blood pressures at dosages effective to inhibit contraction of prostate tissue.
• More particularly illustrating the invention is the method of inhibiting contraction of prostate tissue or relaxing urethral smooth muscle wherein the compound (or composition) is administered in combination with a testosterone 5-alpha reductase inhibitor; preferably, the testosterone 5-alpha reductase inhibitor is finasteride.
• More particularly exemplifying the invention is a method of treating a disease which is susceptible to treatment by antagonism of the alpha 1 a receptor which comprises administering to a subject in need thereof an amount of any of the compounds described above effective to treat the disease.
• Diseases which are susceptible to treatment by antagonism of the alpha 1 a receptor include, but are not limited to, BPH, high intraocular pressure, high cholesterol, impotency, sympathetically mediated pain and cardiac arrhythmia.
• An additional illustration of the invention is the use of any of the compounds described above in the preparation of a medicament for: a) the treatment of benign prostatic hype ⁇ lasia; b) relaxing urethral smooth muscle; or c) inhibiting contraction of prostate tissue; in a subject in need thereof.
• An additional example of the invention is a drug which is useful for: a) treating benign prostatic hype ⁇ lasia; b) relaxing urethral smooth muscle; or c) inhibiting contraction of prostate tissue; in a subject in need thereof, the effective ingredient of the said drug being any of the compounds described above.
• Representative compounds of the present invention exhibit high selectivity for the human alpha la adrenergic receptor.
• One implication of this selectivity is that these compounds display selectivity for lowering intraurethral pressure without substantially affecting diastolic blood pressure.
• Representative compounds of this invention display submicromolar affinity for the human alpha la adrenergic receptor subtype while displaying at least ten-fold lower affinity for the human alpha Id and alpha lb adrenergic receptor subtypes, and many other G- protein coupled human receptors.
• Particular representative compounds of this invention exhibit nanomolar and subnanomolar affinity for the human alpha la adrenergic receptor subtype while displaying at least 30 fold lower affinity for the human alphald and alprenz adrenergic receptor subtypes, and many other G-protein coupled human receptors.
• Preferred compounds of this invention exhibit Ki's for human alpha la adrenergic receptors which are more than 400 fold lower than for the human alphal d or alpschreib adrenergic receptors, while exhibiting greater than 500 fold selectivity for the human alpha la adrenergic receptor over all other human G-protein coupled receptors tested (including serotonin, dopamine, alpha 2 adrenergic, beta adrenergic or muscarinic receptors).
• salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts.”
• Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
• Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
• suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
• representative pharmaceutically acceptable salts include the following:
• Glycollylarsanilate Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Nitrate, N-methylglucamine ammonium salt, Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Salicylate, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide and Valerate.
• the present invention includes within its scope prodrugs of the compounds of this invention.
• prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
• Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu. Where the compounds according to the invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more chiral centers, they may additionally exist as diastereoisomers.
• alkyl shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, l -propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
• alkenyl shall mean straight or branched chain alkenes of two to ten total carbon atoms, or any number within this range.
• aryl refers to unsubstituted, mono- or poly-substituted aromatic groups such as phenyl or naphthyl.
• cycloalkyl shall mean cyclic rings of alkanes of three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
• alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aralkoxyaryloxy) it shall be inte ⁇ reted as including those limitations given above for "alkyl” and "aryl.”
• Designated numbers of carbon atoms e.g., C] -io shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
• halogen shall include iodine, bromine, chlorine and fluorine.
• substituted shall be deemed to include multiple degrees of substitution by a named substitutent.
• poly- substituted as used herein shall include di-, tri-, tetra- and penta- substitution by a named substituent.
• substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally.
• heterocycle or heterocyclic ring represents an unsubstituted or substituted stable 5- to 7-membered monocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from N, O or S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
• the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
• heterocyclic groups include, but is not limited to, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl, furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazoHdinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, mo ⁇ holinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl, tetrahydropyranyl, thiamo ⁇ holinyl, thiam
• subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
• terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
• compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier.
• these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
• the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
• the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
• a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water
• a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate
• This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
• the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
• the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
• the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
• enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
• composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
• liquid forms in which the novel compositions of the present invention may be inco ⁇ orated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
• Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
• the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers
• these isomers may be separated by conventional techniques such as preparative chromatography.
• the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
• the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d- tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
• the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
• any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. John Wiley & Sons, 1991.
• the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
• the specificity of binding of compounds showing affinity for the ⁇ i a receptor is shown by comparing affinity to membranes obtained from tranfected cell lines that express the ⁇ ia receptor and membranes from cell lines or tissues known to express other types of alpha (e.g., aid, aib) or beta adrenergic receptors.
• Expression of the cloned human aid, aib, and ⁇ ia receptors and comparison of their binding properties with known selective antagonists provides a rational way for selection of compounds and discovery of new compounds with predictable pharmacological activities.
• Antagonism by these compounds of the human alpha la adrenergic receptor subtype may be functionally demonstrated in anesthetized animals. These compounds may be used to increase urine flow without exhibiting orthostatic hypotensive effects.
• the cloned human ⁇ ia receptor when expressed in mammalian cell lines, is used to discover ligands that bind to the receptor and alter its function. Expression of the cloned human aid. ai b, and ⁇ ia receptors and comparison of their binding properties with known selective antagonists provides a rational way for selection of compounds and discovery of new compounds with predictable pharmacological activities. Compounds of this invention exhibiting selective human ⁇ i a adrenergic receptor antagonism may further be defined by counterscreening. This is accomplished according to methods known in the art using other receptors responsible for mediating diverse biological functions. rSee e.g.. PCT International Application Publication No. WO94/10989, published 26 May 1994; U.S. Patent No.
• compositions containing compounds of this invention as the active ingredient for use in the specific antagonism of human alpha 1 a adrenergic receptors can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for systemic administration.
• the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
• they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
• an effective but non-toxic amount of the compound desired can be employed as an alpha la antagonistic agent.
• compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
• compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
• the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
• the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, .age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
• a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
• Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
• the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier” materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
• carrier suitable pharmaceutical diluents, excipients or carriers
• the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
• suitable binders, lubricants, disintegrating agents and coloring agents can also be inco ⁇ orated into the mixture.
• suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
• Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
• Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
• the liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
• Other dispersing agents which may be employed include glycerin and the like.
• sterile suspensions and solutions are desired.
• Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
• the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
• Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
• Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
• the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
• Such polymers can include polyvinyl ⁇ pyrrolidone, pyran copolymer, polyhydroxypropylmethacryl- amidephenol, polyhydroxy-ethylaspartamidephenol, or polyethyl- eneoxidepolylysine substituted with palmitoyl residues.
• the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-pyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
• a drug for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-pyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
• Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific blockade of the human alpha 1 a adrenergic receptor is required.
• the daily dosage of the products may be varied over a wide range from 0.01 to 1 ,000 mg per adult human per day.
• the compositions are preferably provided in the form of tablets containing 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0 and 100 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
• a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient.
• An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 250 mg/kg of body weight per day.
• the range is from about 0.001 to 100 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
• the compounds may be administered on a regimen of 1 to 4 times per day.
• Compounds of this patent disclosure may be used alone at appropriate dosages defined by routine testing in order to obtain optimal antagonism of the human ⁇ ia adrenergic receptor while minimizing any potential toxicity.
• co-administration or sequential administration of other agents which alleviate the effects of BPH is desirable.
• this includes administration of compounds of this invention and a human testosterone 5- ⁇ reductase inhibitor. Included with this embodiment are inhibitors of 5-alpha reductase isoenzyme 2.
• PROSCAR® also known as finasteride, a 4-Aza-steroid; see US Patents 4,377,584 and 4,760,071 , for example, hereby inco ⁇ orated by reference.
• PROSCAR® which is principally active in prostatic tissue due to its selectivity for human 5- ⁇ reductase isozyme 2
• combinations of compounds which are specifically active in inhibiting testosterone 5- alpha reductase isozyme 1 and compounds which act as dual inhibitors of both isozymes 1 and 2 are useful in combination with compounds of this invention.
• the dosages of the alpha 1 a adrenergic receptor and testosterone 5-alpha reductase inhibitors are adjusted when combined to achieve desired effects.
• dosages of the 5-alpha reductase inhibitor and the alpha la adrenergic receptor antagonist may be independently optimized and combined to achieve a synergistic result wherein the pathology is reduced more than it would be if either agent were used alone.
• the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be inte ⁇ reted accordingly.
• a method of treating BPH comprises administering to a subject in need of treatment any of the compounds of the present invention in combination with finasteride effective to treat BPH.
• the dosage of finasteride administered to the subject is about 0.01 mg per subject per day to about 50 mg per subject per day in combination with an ⁇ ia antagonist.
• the dosage of finasteride in the combination is about 0.2 mg per subject per day to about 10 mg per subject per day, more preferably, about 1 to about 7 mg per subject to day, most preferably, about 5 mg per subject per day.
• compounds of this invention exhibiting alpha 1 a adrenergic receptor blockade can be combined with a therapeutically effective amount of a 5 ⁇ -reductase 2 inhibitor, such as finasteride, in addition to a 5 ⁇ - reductase 1 inhibitor, such as 4,7 ⁇ -dimethyl-4-aza-5 ⁇ -cholestan-3- one, in a single oral, systemic, or parenteral pharmaceutical dosage formulation.
• a combined therapy can be employed wherein the alpha la adrenergic receptor antagonist and the 5 ⁇ - reductase 1 or 2 inhibitor are administered in separate oral, systemic, or parenteral dosage formulations. See, e.g., U.S. Patent No.'s 4,377,584 and 4,760,071 which describe dosages and formulations for 5 ⁇ -reductase inhibitors.
• BOPC1 bis(2-oxo-3-oxazolidinyl)phosphinic chloride
• Cbz-Cl benzyloxycarbonyl chloride
• EDCI 1 -(3-dimethylaminopropyI)-3-ethylcarbodimide hydrochloride
• Et3N triethylamine
• EtOAc ethyl acetate
• FABLRMS fast atom bombardment low resolution mass spectroscopy
• HMPA hexamethylphosporamide
• HPLC high performance liquid chromatography
• HOBt 1 -hydroxy benzotriazole hydrate
• i-PrOH 2-propanol
• i-Pr2NEt diisopropylethylamine
• mCPBA meta-chloroperbenzoic acid
• PCTLC preparative centrifugal thin layer chromatography
• PEI polyethylenimine
• Ph phenyl
• TEBAC benzyltriethylammonium chloride
• TFA trifluoroacetic acid
• TMS trimethylsilyl
• the piperidine 4 was alkylated with the bromoalkyl amides lOa-k, which were prepared via coupling of the acetic acid derivatives 8a-k to bromopropyl or bromoethyl amine prior to alkylation.
• N-(3-amino)propyl-4-(2-chlorophenyl)-4-cyanopiperidine dihvdrochloride A solution of saturated HCl-EtOAc (200 ml) was added to 4-(2-Chlorophenyl)-4-cyano-N-(3-[N- ⁇ 1 ,1 - dimethylethoxycarbonyl ⁇ ]amino)propylpiperidine (1.12 mg, 3.0 mmol). The resulting mixture was allowed to react for 1 hour at room temperature. The EtOAc was removed in vacuo affording 4-(2- chlorophenyl)-4-cyano-/V-(3-amino)propyI-piperidine dihydrochloride as a white solid.
• PCTLC (Si ⁇ 2, 4 mm, 1 :1 hexane: EtOAc) afforded -[4-(2-chlorophenyl)-4-cyano-piperidin-l- yl)propyl]-2-[bis(4-methyl-phenyl)]-acetamide as a white powder.
• FABLRMS 1 mixture of dithiothreitol and dithioerythritol in MeOH
• the aqueous phase was extracted with CH 2 CI 2 (2 x 5.0 mL) and the combined organic extracts were washed with water (3 x 10 mL) and saturated aqueous NaCl (1 x 10 mL), dried (Na 2 S ⁇ 4), and concentrated in vacuo.
• 17b as the hydrochloride salt after treatment with methanolic HCl.
• 17a NMR (CDC1 3 , 400 MHz) consistant with assigned structure.
• FABLRMS m/e 459 g/mole (M++H, C 25 H 32 F 2 N 4 O 2 459 g/mole.)
• 100 mg of the compound of Example 12 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
• the objective of this assay is to eliminate agents which specifically affect binding of [3H] spiperone to cells expressing human dopamine receptors D2, D3 or D4.
• the assay is initiated by adding 50-75 ⁇ g membranes in a total volume of 500 ⁇ l containing 0.2 nM [3H] -spiperone. Non-specific binding is defined using 10 ⁇ M apomorphine.
• the assay is terminated after a 2 hour incubation at room temperature by rapid filtration over GF/B filters presoaked in 0.3% PEI, using 50mM Tris-HCl pH 7.4.
• the objective of this assay is to eliminate agents which specifically affect binding to cloned human 5HTla receptor
• Mammalian cells expressing cloned human 5HTla receptors are lysed in ice-cold 5 mM Tris-HCl , 2 mM EDTA (pH 7.4) and homogenized with a polytron homogenizer. The homogenate is centrifuged at lOOOXg for 30', and then the supernatant is centrifuged again at 38,000Xg for 30'.
• the binding assay contains 0.25 nM [3H]8- OH-DPAT (8-hydroxy-2-dipro ⁇ ylamino-l ,2,3,4-tetrahydronaphthalene) in 50 mM Tris-HCl, 4 mM CaC12 and 1 mg/ml ascorbate. Non-specific binding is defined using 10 ⁇ M propranolol. The assay is terminated after a 1 hour incubation at room temperature by rapid filtration over
• Taconic Farms Sprague-Dawley male rats, weighing 250- 400 grams are sacrificed by cervical dislocation under anesthesia (methohexital; 50 mg/kg, i.p.). An incision is made into the lower abdomen to remove the ventral lobes of the prostate.
• Each prostate removed from a mongrel dog is cut into 6-8 pieces longitudinally along the urethra opening and stored in ice-cold oxygenated Krebs solution overnight before use if necessary.
• Dog urethra proximal to prostate is cut into approximately 5 mm rings, the rings are then cut open for contractile measurement of circular muscles.
• Human prostate chips from transurethral surgery of benign prostate hype ⁇ lasia are also stored overnight in ice-cold Krebs solution if needed.
• the tissue is placed in a Petri dish containing oxygenated Krebs solution [NaCl, 1 18 mM; KCI, 4.7 mM; CaCl2, 2.5 mM; KH2PO4, 1.2 mM; MgS04, 1.2 mM; NaHC03, 2.0 mM; dextrose, 1 1 mM] warmed to 37°C. Excess lipid material and connective tissue are carefully removed.
• Tissue segments are attached to glass tissue holders with 4-0 surgical silk and placed in a 5 ml jacketed tissue bath containing Krebs buffer at 37°C, bubbled with 5% C ⁇ 2/95% 02-
• the tissues are connected to a Statham-Gould force transducer; 1 gram (rat, human) or 1.5 gram (dog) of tension is applied and the tissues are allowed to equilibrate for one hour. Contractions are recorded on a Hewlett-Packard 7700 series strip chart recorder.
• Benign prostatic hype ⁇ lasia causes a decreased urine flow rate that may be produced by both passive physical obstruction of the prostatic urethra from increased prostate mass as well as active obstruction due to prostatic contraction.
• Alpha adrenergic receptor antagonists such as prazosin and terazosin prevent active prostatic contraction, thus improve urine flow rate and provide symptomatic relief in man.
• these are non-selective alpha- 1 receptor antagonists which also have pronounced vascular effects. Because we have identified the alpha- la receptor subtype as the predominent subtype in the human prostate, it is now possible to specifically target this receptor to inhibit prostatic contraction without concomitant changes in the vasculature.
• the following model is used to measure adrenergically mediated changes in intra-urethral pressure and arterial pressure in anesthetized dogs in order to evaluate the efficacy and potency of selective alpha adrenergic receptor antagonists.
• the goals are to: 1 ) identify the alpha- 1 receptor subtypes responsible for prostatic/urethral contraction and vascular responses, and 2) use this model to evaluate novel selective alpha adrenergic antagonists. Novel and standard alpha adrenergic antagonists may be evaluated in this manner.
• the dogs are anesthetized with pentobarbital sodium (35 mg/kg, i.v. plus 4 mg/kg/hr iv infusion).
• An endotracheal tube is inserted and the animal ventilated with room air using a Harvard instruments positive displacement large animal ventilator.
• Catheters PE 240 or 260
• Catheters are placed in the aorta via the femoral artery and vena cava via the femoral veins (2 catheters, one in each vein) for the measurement of arterial pressure and the administration of drugs, respectively.
• a supra-pubic incision ⁇ l/2 inch lateral to the penis is made to expose the urethers, bladder and urethra.
• the urethers are ligated and cannulated so that urine flows freely into beakers.
• the dome of the bladder is retracted to facilitate dissection of the proximal and distal urethra.
• Umbilical tape is passed beneath the urethra at the bladder neck and another piece of umbilical tape is placed under the distal urethra approximately 1-2 cm distal to the prostate.
• the bladder is incised and a Millar micro-tip pressure transducer is advanced into the urethra.
• the bladder incision is sutured with 2-0 or 3-0 silk (purse-string suture) to hold the transducer.
• Phenylephrine an alpha- 1 adrenergic agonist
• Phenylephrine an alpha- 1 adrenergic agonist
• the relative antagonist potency on phenylephrine induced changes in arterial and intra-urethral pressure are determined by Schild analysis.
• the family of averaged curves are fit simultaneously (using ALLFIT software package) with a four paramenter logistic equation constraining the slope, minimum response, and maximum response to be constant among curves.
• the dose ratios for the antagonist doses (rightward shift in the dose-response curves from control) are calculated as the ratio of the ED50's for the respective curves. These dose-ratios are then used to construct a Schild plot and the Kb (expressed as ug/kg, iv) determined.
• the Kb dose of antagonist causing a 2-fold rightward shift of the phenylephrine dose-response curve
• the relative selectivity is calculated as the ratio of arterial pressure and intra-urethral pressure Kb's. Effects of the alpha- 1 antagonists on baseline arterial pressure are also monitored. Comparison of the relative antagonist potency on changes in arterial pressure and intra-urethral pressure provide insight as to whether the alpha receptor subtype responsible for increasing intra-urethral pressure is also present in the systemic vasculature. According to this method, one is able to confirm the selectivity of alpha la adrenergic receptor antagonists that prevent the increase in intra- urethral pressure to phenylephrine without any activity at the vasculature.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=23939051

Family Applications (1)

Country Status (5)

Families Citing this family (24)

Citations (9)

Family Cites Families (18)

• 1995
  • 1995-06-07 US US08/488,272 patent/US5661163A/en not_active Expired - Fee Related
• 1996
  • 1996-06-06 US US08/973,624 patent/US5977115A/en not_active Expired - Lifetime
  • 1996-06-06 CA CA002221744A patent/CA2221744A1/en not_active Abandoned
  • 1996-06-06 EP EP96919191A patent/EP0833637A4/de not_active Withdrawn
  • 1996-06-06 JP JP9501746A patent/JPH11507344A/ja not_active Withdrawn
  • 1996-06-06 WO PCT/US1996/009425 patent/WO1996040136A1/en not_active Application Discontinuation
• 1999
  • 1999-06-30 US US09/345,652 patent/US6274583B1/en not_active Expired - Fee Related

Patent Citations (9)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events